Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Science 37

company

About

Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.

Details

Last Funding Type
Series D
Last Funding Money Raised
$35M
Industries
Biotechnology,Clinical Trials,Health Care,Home Health Care
Founded date
Jan 1, 2014
Number Of Employee
251 - 500
Operating Status
Active
Stock Symbol
nasdaq:SNCE
Legal Name
Science 37, Inc.

Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$582.50M
Science 37 has raised a total of $582.50M in funding over 2 rounds. Their latest funding was raised on Oct 7, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 7, 2021 Post-IPO Equity $200M 14 Detail
Oct 7, 2021 IPO $235M Detail
Aug 20, 2020 Series Unknown $40M 10 Lux Capital
Pharmaceutical Product Development
Redmile Group
Detail
Jan 3, 2019 Series D $35M 6 Pharmaceutical Product Development Detail
Apr 25, 2017 Series C $35M 7 Glynn Capital Management Detail

Employee Profiles

Number of Employee Profiles
23
Science 37 has 23 current employee profiles, including Executive Christine Pellizzari
Employee
Executive
Executive
Executive